1: gained access to disaggregated data on incidence, hospital admissions, contact tracing etc. and to (sero-)surveillance; whenever possible, data was shared as open data or as part of data visualization dashboards
2: estimation of key epidemiological parameters (incubation/generation time, basic reproduction number, proportion of pre-symptomatic infections, IFR, hospital capacity, mortality) and on robust methods to deal with various sources of error/bias. Real-time estimates of Re have been made available via online dashboards.
3: real-time modelling has provided national authorities with regular updates to projections of morbidity and mortality under different intervention scenarios; assessed excess mortality using a model that forecasts subject-specific mortality using historical data
4: set up realtime health care pressure evaluation methods and tools,
https://www.covid-hcpressure.org/home/(öffnet in neuem Fenster); incorporation of QoL measurements in citizen science initiatives: the Great Corona Study, Influenzanet; developed mathematical models to evaluate the effect of different scenarios of control & relaxation strategies on hospital and ICU burden
5: collected social contact and risk perception data through the CoMix survey in >20 countries, yielding several publications, Comix reports were used directly for policy advice in several countries; analysed the relationship between media coverage, epidemic progression, and users’ collective web-based response; gained access to data from the Great Corona Survey
6: worked on the impact of NPIs (teleworking, school closure, social distancing, restricted social contacts (‘bubbles’), travel restrictions) and of testing policies, antivirals, and different vaccination strategies on mitigating local epidemics using mathematical and statistical models and CoMix data
7: populated a database of macroeconomic parameters of 27 EU countries that can be used as inputs for CGE models, applied the CGE model to UK data
8: performed an economic analysis of COVID-19 vaccination in the UK and collaborated with other consortia to investigate affordability, funding and pricing of vaccines in the context of global accessibility, also vaccine roll-out and its effect on the general economic equilibrium
9: made results rapidly available to the scientific and public health communities; fostered collaboration with many scientific partners and participated in advisory bodies and public health networks; initiatives taken to foster engagement with the wider public.
139 scientific outputs
>3500 downloads of CoMix Belgian
>300 media coverage received
>29 national and international advisory bodies